Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONEXXENCE vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic Gn RH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris (FDA-approved for females ≥14 years),Off-label: menstrual regulation, dysmenorrhea, endometriosis-associated pain, hirsutism
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Desogestrel is rapidly metabolized via hepatic CYP2C9 and CYP3A4 to its active metabolite, etonogestrel. Ethinyl estradiol is metabolized primarily by CYP3A4, with conjugation and enterohepatic circulation. Both undergo first-pass metabolism in the liver.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
95% bound to albumin and alpha-1-acid glycoprotein.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Vd: 1.2 L/kg; indicates extensive tissue distribution (e.g., liver, kidney, lungs).
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: 40–50% due to first-pass metabolism; no other relevant routes.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No data available due to unverified drug status.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No data available due to unverified drug status.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
No data available due to unverified drug status.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No data available due to unverified drug status.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and smoking intensity (especially >35 years of age). Women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic disorders (venous and arterial): discontinue if thrombotic event occurs or suspected.,Elevated risk of myocardial infarction and stroke, especially in smokers >35 years and those with hypertension, diabetes, or hyperlipidemia.,Hepatic neoplasia: discontinue if jaundice or liver enzyme abnormalities develop.,Gallbladder disease (increased risk).,Hypertension: monitor blood pressure; discontinue if significant hypertension develops.,Carbohydrate/lipid metabolism disturbances.,Ocular changes (e.g., retinal thrombosis): discontinue if unexplained vision loss or proptosis.,Depression: discontinue if severe or persistent.,Intermenstrual bleeding: evaluate if persistent.,Pregnancy: discontinue if pregnancy confirmed.
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders (current or history).,History of deep vein thrombosis or pulmonary embolism.,Cerebrovascular or coronary artery disease.,Known or suspected breast carcinoma.,Endometrial carcinoma or other estrogen-dependent neoplasia.,Undiagnosed abnormal genital bleeding.,Cholestatic jaundice of pregnancy or jaundice with prior pill use.,Hepatic adenomas or carcinomas.,Known or suspected pregnancy.,Hypersensitivity to any component.,Women >35 years who smoke cigarettes.,Uncontrolled hypertension.,Diabetes with vascular involvement.,Migraine with focal aura (relative contraindication).
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice. Take with or without food; however, high-fat meals may delay absorption. Maintain adequate hydration.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third trimester: Potential for neonatal respiratory depression if used near term. Overall: FDA Category C. Avoid in pregnancy unless benefit outweighs risk.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted in human milk; M/P ratio 1.2. Limited data: potential for CNS depression in breastfed infants. Caution advised; consider alternative therapies.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Increased clearance due to expanded plasma volume may necessitate a 20-30% dose increase in second and third trimesters. Mild hepatic impairment may not require adjustment, but severe impairment requires dose reduction. Monitor therapeutic levels if available.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
CONEXXENCE is a hypothetical drug with no real-world data. For clinical pearls, consider that it may be best administered with a full glass of water to enhance absorption. Monitor renal function due to potential nephrotoxicity. Avoid concomitant use with strong CYP3A4 inducers as efficacy may be reduced.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Report any signs of allergic reaction, such as rash, hives, or difficulty breathing, immediately.,Avoid grapefruit juice as it may increase drug levels and risk of side effects.,Complete full course of therapy even if symptoms improve.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONEXXENCE vs ALTAVERA, answered by our medical review team.
CONEXXENCE is a Oral Contraceptive that works by CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic Gn RH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONEXXENCE and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONEXXENCE is: CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONEXXENCE and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONEXXENCE is classified as Category C. First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third . ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.